361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
| Autor: | Wu, C., Strickler, J.H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Paulson, A.S., Hubbard, J., Coveler, A., Fountzilas, C., Kardosh, A., Kasi, P.M., Lenz, H.J., Ciombor, K.K., Elez Fernandez, M.E., Hsu, L-I., Stecher, M., Zhao, K., Bekaii-Saab, T. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S700-S701 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|